Bracco, a global leader in diagnostic imaging, and ulrich GmbH & Co. KG, a renowned German medical device manufacturer specializing in contrast media i...
Medtronic plc announced financial results for its second quarter of fiscal year 2024 (FY24), which ended October 27, 2023. Key Highlights Revenue of $8...
GE HealthCare (Nasdaq: GEHC) has received U.S. FDA 510(k) Clearance for the new version of Digital Expert Access with remote scanning, the first remote pat...
Major Milestone Met in AI-Powered Fight Against Lung Cancer Global initiative gains significant ground in digitally identifying cancer risk before s...
“We are proud to reach this incredible milestone of more than 100,000 patients with the support of our surgeon partners worldwide,” said Exacte...
Approval is the culmination of ten years of clinical research and development of the Medtronic renal denervation technology Medtronic plc (NYSE: MDT), a ...
The oversubscribed capital raise was led by existing venture capital investors: U.S. Venture Partners, Norwest Venture Partners, InnovaHealth Partners, and...
Royal Philips (NYSE: PHG, AEX: PHIA) a global leader in health technology, and NYU Langone Health, the nation’s top-ranked academic medical cen...
The SOPHIE program supports collaborative projects for Ontario-based life science firms in the later stages of commercialization. DiagnaMed can leverage fu...
“The close of the LimFlow acquisition allows us to begin to integrate this exciting technology that is offering new hope to patients suffering from C...
Claritas, a leader in image enhancement and AI diagnostic solutions has developed pioneering technology for real-time precision detection of conditions in ...
Olympus assessed the issue after receiving complaints of adverse events involving serious patient injury, where patients may suffer burns to the airway or ...
The new implants provide orthopaedic surgeons with additional tibial height options for total ankle replacement patients. Both implants are 3D-printed and ...
Lunit SCOPE IO pivotal in first phase III trial successfully showing the efficacy of immunotherapy + chemotherapy for NSCLC patients with EGFR or ALK mut...
© 2025 Biopharma Boardroom. All Rights Reserved.
